Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis

Atherosclerosis

Volumn 141, Issue 1, 1998, Pages 1-15

  Heinecke, Jay W ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8046   (United States)

Author keywords

Atherogenesis; Atherosclerosis; Lipoxygenase; Low density lipoproteins; Myeloperoxidase; Oxidation

Indexed keywords

ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; OXIDIZING AGENT; REACTIVE OXYGEN METABOLITE;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; DEFENSE MECHANISM; FEMORAL ARTERY; HUMAN; HYPOTHESIS; LIPID OXIDATION; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032487487     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00173-7     Document Type: Review

References (158)

1. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34.
2. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76:1979;333.
3. Fogelman A.M., Shechter I., Seager J., Hokom M., Child J.S., Edwards P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl. Acad. Sci. USA. 77:1980;2214.
4. Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. USA. 78:1981;6499.
5. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1991;1785.
6. Esterbauer H., Gebicki J., Puhl H., Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free. Radic. Biol. Med. 13:1992;341.
7. Navab M., Berliner J.A., Watson A.D. et al. The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16:1996;831.
8. Berliner J.A., Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free. Radic. Biol. Med. 20:1996;707.
9. Heinecke J.W., Rosen H., Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J. Clin. Invest. 74:1984;1890.
10. Morel D.W., DiCorleto P.E., Chisolm G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4:1984;357.
11. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA. 81:1984;3883.
12. Daugherty A., Zweifel B.S., Sobel B.E., Schonfeld G. Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis. 8:1988;768.
13. Yla-Herttuala S., Palinski W., Rosenfeld M.E. et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086.
14. Haberland M.E., Cheng L., Fong D. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:1988;215.
15. Rosenfeld M.E., Palinski W., Yla-Herttuala S., Butler S., Witztum J.L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein-B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:1990;336.
16. Lynch S.M., Frei B. Antioxidants as anti-atherogens: animal studies. Frei B. Natural antioxidants in human health and disease. 1994;Academic Press, Orlando, FL.
17. Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet. 346:1995;36.
18. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Antioxidants and atherosclerotic heart disease. New. Eng. J. Med. 337:1997;408.
19. Frei B., Stocker R., Ames B.N. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc. Natl. Acad. Sci. USA. 85:1988;9748.
20. Parthasarathy S., Printz D.J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 6:1986;505.
21. Hiramatsu K., Rosen H., Heinecke J.W., Wolfbauer G., Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis. 7:1987;55.
22. Ehrenwald E., Chisolm G.M., Fox P.L. Intact ceruloplasmin oxidatively modifies low density lipoprotein. J. Clin. Invest. 93:1994;1493.
23. Mukhopadhyay C.K., Mazumder B., Lindley P.F., Fox P.L. Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. Proc. Natl. Acad. Sci. USA. 94:1997;11546.
24. Heinecke J.W., Baker L., Rosen H., Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J. Clin. Invest. 77:1986;757.
25. Heinecke J.W., Suzuki L., Rosen H., Chait A. The role of sulfur containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J. Biol. Chem. 262:1987;10098.
26. Lynch S.M., Frei B. Mechanisms of copper- and iron-dependent oxidative modification of human low density lipoprotein. J. Lipid. Res. 34:1993;1745.
27. Sparrow C.P., Olszewski J. Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. J. Lipid. Res. 34:1993;1219.
28. Heinecke J.W., Kawamura M., Suzuki L., Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J. Lipid. Res. 34:1993;2051.
29. Lynch S.M., Frei B. Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. Biochem. Biophys. Acta. 1345:1997;215.
30. Bowry V.W., Stocker R. Tocopherol-mediated peroxidation: the prooxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein. J. Am. Chem. Soc. 115:1993;6029.
31. Ingold K.U., Bowry V.W., Stocker R., Walling C. Autoxidation of lipids and antioxidation by α-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids-unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc. Natl. Acad. Sci. USA. 90:1993;45.
32. Lynch S.M., Frei B. Reduction of copper, but not iron, by human low density lipoprotein (LDL)-implications for metal ion-dependent oxidative modification of LDL. J. Biol. Chem. 270:1995;5158.
33. Kontush A., Meyer S., Finckh B., Kohlschutter A., Beisiegel U. α-Tocopherol as a reductant for Cu(II) in human lipoproteins-triggering role in the initiation of lipoprotein oxidation. J. Biol. Chem. 271:1996;11106.
34. Frei B., Gaziano J.M. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation. J. Lipid. Res. 34:1993;2135.
35. 2+-stimulated oxidation of low-density lipoprotein. Arch. Biochem. Biophys. 315:1994;244.
36. Miotti G., Aust S.D. The requirement for iron(III) in the initiation of lipid peroxidation by iron(II) and hydrogen peroxide. J. Biol. Chem. 262:1987;1098.
37. Kuzuya M., Yamada K., Hayashi T., Funaki C., Naito M., Asai K., Kuzuya F. Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low-density lipoprotein. Biochem. Biophys. Acta. 1123:1992;334.
38. Gieseg S.P., Esterbauer H. Low density lipoprotein in saturable by pro-oxidant copper. FEBS. Lett. 343:1994;188.
39. Ziouzenkova O., Gieseg S.P., Ramos P., Esterbauer H. Factors affecting resistance of low density lipoproteins to oxidation. Lipids. 31:1996;71.
40. Chen K., Frei B. The effect of histidine modification on copper-dependent lipid peroxidation in human low-density lipoprotein. Redox. Rep. 3:1997;175.
41. Wagner P., Heinecke J.W. Copper ions promote peroxidation of low density lipoprotein lipid by binding to histidine residues of apolipoprotein B100, but they are reduced at other sites on LDL. Arterioscler. Thromb. Vasc. Biol. 17:1997;3338.
42. Heinecke J.W. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr. Opin. Lipidol. 8:1997;268.
43. Morrow J.D., Roberts L.J. The isoprostanes: current knowledge and directions for future research. Biochem. Pharmmacol. 51:1996;1.
44. Patrono C., FitzGerald G.A. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;2309.
45. Leuwenburgh C., Rasmussen J.E., Hsu F.F., Mueller D.M., Pennathur S., Heinecke J.W. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J. Biol. Chem. 272:1997;3520.
46. Huggins T.G., Wells-Knecht M.C., Detorie N.A., Baynes J.W., Thorpe S.R. Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. J. Biol. Chem. 268:1993;12341.
47. Bothwell T.H., Charlton R.W., Cook J.D., Finch C.A. Iron metabolism in man. 1979;Blackwell Scientific Pub, Oxford.
48. Danks D.M. Disorders of copper transport. Scriver C.R., Beaudet A.L., Sly W.S., Valley D. The metabolic basis of inherited disease. 6th ed:1989;1411 McGraw-Hill, New York.
49. Miller M., Hutchins G.M. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. J. Am. Med. Assoc. 272:1994;231.
50. Ascherio A., Willett W.C. Are body iron stores related to the risk of coronary heart disease? New. Eng. J. Med. 330:1994;1152.
51. Smith C., Mitchinson M.J., Aruoma O.I., Halliwell B. Stimulation of lipid peroxidation and hydroxyl radical generation by the contents of human atherosclerotic lesions. Biochem. J. 286:1992;901.
52. Swain J., Gutteridge J.M.C. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activity in human atherosclerotic material. FEBS. Let. 368:1995;513.
53. Lamb D., Mitchinson M.J., Leake D.S. Transition metals within human atherosclerotic lesions can catalyze the oxidation of low density lipoprotein by macrophages. FEBS. Let. 374:1995;12.
54. Dabbagh A.J., Shwaery G.T., Keaney J.F., Frei B. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler. Thromb. Vasc. Biol. 17:1997;2638.
55. Araujo J.A., Romano E.L., Brito B.E. et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;1172.
56. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochem. Biophys. Acta. 1128:1992;117.
57. Sparrow C.P., Parthasarathy S., Steinberg D. Enzymatic modification of LDL by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J. Lipid. Res. 29:1988;745.
58. Parthasarathy S., Weiland E., Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 86:1989;1046.
59. Jessup W., Darley-Usmar V., O'Leary V., Bedwell O.S. 5-Lipoxygenase is not essential for macrophage mediated oxidation of LDL. Biochem. J. 278:1991;163.
60. Sparrow C.P., Olszewski J. Cellular oxidative modification of LDL does not require lipoxygenases. Proc. Natl. Acad. Sci. USA. 89:1991;128.
61. Yla-Herttuala S., Rosenfeld M.E., Parthasarathy S., Sigal E., Sarkioia T., Witztum J.L., Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 87:1987;6959.
62. Yla-Herttuala S., Luoma J., Viita H., Hiltunen T., Sisto T., Nikkari T. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J. Clin. Invest. 95:1995;2692.
63. Benz D.J., Mol M., Ezaki M. et al. Enhanced levels of lipoperoxides in low density lipoprotein incubated with fibroblasts expressing high levels of human 15-lipoxygenase. J. Biol. Chem. 270:1995;5191.
64. Sigari F., Lee C., Witztum J.L., Reaven P.D. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL. Arterioscler. Thromb. Vasc. Biol. 17:1997;3639.
65. Belkner J., Wiesner R., Rathman J., Barnett J., Sigal E., Kuhn H. Oxygenation of lipoproteins by mammalian lipoxygenases. Eur. J. Biochem. 213:1993;251.
66. Folcik V.A., Nivar-Aristy R.A., Krajewski L.P., Cathcart M.K. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J. Clin. Invest. 96:1995;504.
67. Kuhn H., Heydeck D., Hugou I., Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherosclerosis. J. Clin. Invest. 99:1997;888.
68. Rao S.I., Wilks A., Hamberg M., Ortiz de Montellano P.R. The lipoxygenase activity of myoglobin. J. Biol. Chem. 269:1994;7210.
69. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:1991;109.
70. Cooke J.P., Tsao P.S. Is NO an endogenous antiatherogenic molecule? Arterioscler. Thromb. 14:1994;653.
71. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA. 87:1990;1620.
72. Graham A.N., Hogg N., Kalyanaraman B., O'Leary V., Darley-Usmar V., Moncade S. Peroxynitrite modifications of LDL leads to recognition by the macrophage scavenger receptor. FEBS. Lett. 330:1993;181.
73. Beckman J.S., Chen J., Ischiropoulos H., Crow J.P. Oxidative chemistry of peroxynitrite. Methods. Enzymol. 233:1994;229.
74. Beckman J.S., Ye Y.Z., Anderson P.G., Chen J., Accavitti M.A., Tarpey M.M., White C.R. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. Hoppe-Seyler. 375:1994;81.
75. Jessup W., Mohr D., Gieseg S.P., Dean R.T., Stocker R. The participation of nitric oxide in cell free and its restriction of macrophage-mediated oxidation of low-density lipoprotein. Biochim. Biophys. Acta. 1180:1992;73.
76. Yates M.T., Lambert L.E., Whitten J.P., MacDonald I., Mano M., Ku G., Mao S.J.T. A protective role for nitric oxide in the oxidative modification of low density lipoprotein by mouse macrophages. FEBS. Lett. 309:1992;135.
77. Hogg N., Kalyanaraman B., Joseph J., Struck A., Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS. Lett. 334:1993;170.
78. Rubbo H., Parthasarathy S., Barnes S., Kirk M., Kalyanaraman B., Freeman B.A. Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. Arch. Biochem. Biophys. 324:1995;1.
79. Aji W., Ravalli S., Szabolcs M., Jiang X.-C., Sciacca R.R., Michler R.E., Canon P.J. L-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation. 95:1997;430.
80. Leeuwenburgh C., Hardy M.M., Hazen S.L., Wagner P., Oh-ishi S., Steinbrecher U.P., Heinecke J.W. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerosis. J. Biol. Chem. 272:1997;1433.
81. Klebanoff S.F. Oxygen metabolism and the toxic properties of phagocytes. Ann. Int. Med. 93:1980;480.
82. Hurst J.K., Barette W.C. Leukocytic oxygen activation and microbicidal oxidative toxins. CRC. Crit. Rev. Biochem. Mol. Biol. 24:1989;271.
83. Daugherty A., Rateri D.L., Dunn J.L., Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94:1994;437.
84. Hazell L.J., Arnold L., Flowers D., Waeg G., Malle E., Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97:1996;1535.
85. Zeng J., Fenna R.E. X-ray crystal structure of canine myeloperoxidase at 3Å resolution. J. Mol. Biol. 226:1992;185.
86. Ator M.A., David S.K., Ortiz de Montellano P.R. Structure and catalytic mechanism of horseradish peroxidase. Regiospecific meso alkylation of the prosthetic heme group by alkylhydrazines. J. Biol. Chem. 262:1987;14954.
87. Aeschbach R., Amado R., Neukom H. Formation of dityrosine cross-links in proteins by oxidation of tyrosine residues. Biochem. Biophys. Acta. 439:1976;292.
88. Wieland E., Parthasarathy S., Steinberg D. Peroxidase-dependent metal-independent oxidation of low density lipoprotein in vitro: a model for in vivo oxidation? Proc. Natl. Acad. Sci. USA. 90:1993;5929.
89. Heinecke J.W., Li W., Daehnke H.L., Goldstein J.A. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J. Biol. Chem. 268:1993;4069.
90. Heinecke J.W., Li W., Francis G.A., Goldstein J.A. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J. Clin. Invest. 91:1993;2866.
91. Francis G.A., Mendez A.J., Bierman E.L., Heinecke J.W. Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells. Proc. Natl. Acad. Sci. USA. 90:1993;6631.
92. Savenkova M.I., Mueller D.M., Heinecke J.W. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for initiation of lipid peroxidation in low density lipoprotein. J. Biol. Chem. 269:1994;20394.
93. Karthein R., Dietz R., Nastainczyk W., Ruff H. Higher oxidation states of prostaglandin H synthase. Eur. J. Biochem. 171:1988;313.
94. Buettner G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, α-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300:1993;535.
95. Foti M., Ingold K.U., Lusztyk J. The surprisingly high reactivity of phenoxyl radicals. J. Am. Chem. Soc. 116:1994;9440.
96. Harrison J.E., Schultz J. Studies on the chlorinating activity of myeloperoxidase. J. Biol. Chem. 251:1976;1371.
97. Foote C.S., Goyne T.E., Lehrer R.I. Assessment of chlorination by human neutrophils. Nature. 301:1981;715.
98. Weiss S.J., Test S.T., Eckmann C.M., Ross D., Regiani S. Brominating oxidants generated by human eosinophils. Science. 234:1986;200.
99. Hazen S.L., Hsu F.F., Mueller D.M., Crowley J.R., Heinecke J.W. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J. Clin. Invest. 98:1996;1283.
100. Heinecke J.W., Li W., Mueller D.M., Bohrer A., Turk J. Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide-chloride system: potential markers for lipoproteins oxidatively damaged by phagocytes. Biochemistry. 33:1994;10127.
101. Hazen S.L., Hsu F.F., Duffin K., Heinecke J.W. Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols. J. Biol. Chem. 271:1996;23080.
102. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99:1997;2075.
103. Eiserich J.P., Cross C.E., Jones A.D., Halliwell B., Van der Vliet A. Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid: a novel mechanism for nitric oxide-mediated protein modification. J. Biol. Chem. 271:1996;19199.
104. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., Van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 391:1998;393.
105. Shen J., Herderick E., Cornhill J.F. et al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest. 98:1996;2201.
106. Parthasarathy S., Young S.G., Witztum J.L., Pittman R.C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77:1986;641.
107. Kita T., Nagano Y., Yokode M. et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:1987;5928.
108. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:1987;7725.
109. Sparrow C.P., Deobber T.W., Olszewski J., Wu M.S., Ventre J., Stevens K.A., Chao Y.S. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N-diphenyl-phenylenediamine. J. Clin. Invest. 89:1992;1885.
110. Bjorkhem I, Henriksson-Freyschusi, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 1991;11:15.
111. Tangirala R.K., Casanada F., Miller E., Witztum J.L., Steinberg D., Palinski W. Effect of the antioxidant N,N′-diphenyl-1, 4-phenylenediamine (DPPD) on atherosclerosis in apo E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 15:1995;1625.
112. Bocan T.M.A., Mazur M.J., Mueller S.B., Charlton G., Kieft K.A., Krause B.R. Atherosclerotic lesion development in hypercholesterolemic Japanese quail following probucol treatment: a biochemical and morphologic evaluation. Pharmacol. Res. 29:1994;65.
113. Sasahara M., Raines E.W., Chait A., Carew T.E., Steinberg D., Wahl P.W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in nonhuman primate by probucol. I. Is the extend of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest. 94:1994;155.
114. Kleinveld H.A., Demacker P.N.M., Stalenhoef A.F.H. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. 14:1994;1386.
115. Daugherty A., Zweifel B.S., Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br. J. Pharmacol. 98:1989;612.
116. Nagano Y., Nakamura T., Matsuzawa Y., Cho M., Ueda Y., Kita T. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit-long-term antiatherogenic effect and effects on established plaques. Atherosclerosis. 92:1992;131.
117. Shaish A., Daugherty A., O'Sullivan F., Schonfeld G., Heinecke J.W. Carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J. Clin. Invest. 96:1995;2075.
118. Kleinveld H.A., Hak-Lemmers H.L.M., Hectors M.P.C., de Fouw N.J., Demacker P.N.M., Stalenhoef A.F.H. Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;290.
119. Hazell L.J., Stocker R. Tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS. Lett. 414:1997;541.
120. Parthasarathy S. Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative. J. Clin. Invest. 89:1992;1618.
121. Navab M., Imes S.S., Hmam S.Y. et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocytes chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88:1991;2039.
122. Waldeck A.R., Stocker R. Radical-initiated lipid peroxidation in low density lipoproteins-insights obtained from kinetic modeling. Chem. Res. Toxicol. 9:1996;954.
123. Zhang S.H., Reddick R.L., Avdievich E. et al. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99:1997;2858.
124. Reavens P.D., Parthasarathy S., Belt W.F., Witztum J.L. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler. Thromb. 12:1992;318.
125. Hara S., Nagano Y., Sasada M., Kita T. Probucol pretreatement enhances the chemotaxis of mouse peritoneal macrophages. Arterioscler. Thromb. 12:1992;593.
126. Franceschi G., Chiesa G., Sirtori C.R. Probucol increases cholesteryl ester transfer protein activity in hypercholesterolemic patients. Eur. J. Clin. Invest. 21:1991;348.
127. Suzuki Y.J., Forman H.J., Sevanian A. Oxidants as stimulators of signal transduction. Free. Radic. Biol. Med. 22:1997;269.
128. Devaraj S., Li D., Jialal I. The effects of α-tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 β secretion, and monocyte adhesion to endothelium. J. Clin. Invest. 98:1996;756.
129. Fruebis J., Steinberg D., Dresel H.A., Carew T.E. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J. Clin. Invest. 94:1994;392.
130. Fruebis J., Bird D.A., Pattison J., Palinski W. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J. Lipid. Res. 38:1997;2455.
131. Keaney J.F. Jr, Gaziano J.M., Xu A. et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc. Natl. Acad. Sci. USA. 90:1993;11880.
132. Keaney J.F. Jr, Gaziano J.M., Xu A. et al. Low-dose α-tocopherol improves and high-dose α-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J. Clin. Invest. 93:1994;844.
133. Suarna C., Dean R.T., May J., Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate. Arterioscler. Thromb. Vasc. Biol. 15:1995;1616.
134. Heinecke J.W., Lusis A.J. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am. J. Hum. Genet. 62:1998;20.
135. Tall A.R. Plasma high density lipoproteins. J. Clin. Invest. 86:1990;379.
136. Oram J.F., Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J. Lipid. Res. 37:1996;2473.
137. Parthasarathy S., Barnett J., Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochem. Biophys. Acta. 1044:1990;275.
138. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS. Lett. 286:1991;152.
139. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high-density lipoprotein associated PON: inhibition of the biological activity of minimally oxidized low density lipoproteins. J. Clin. Invest. 96:1995;2882.
140. Berliner J.A., Territo M.C., Sevanian A. et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85:1990;1260.
141. Shig D.M., Gu L., Hama S., Xia Y.-R., Navab M., Fogelman A.M., Lusis A.J. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1996;1630.
142. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J., Brown M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781.
143. Gaziano J.M., Hennekens C.H. Vitamin antioxidants and cardiovascular disease. Curr. Opin. Lipidol. 3:1992;91.
144. Jha P., Flather M., Lonn E., Farkouh M., Yusuf S. The antioxidant vitamins and cardiovascular disease-a critical review of epidemiological and clinical trial data. Ann. Int. Med. 123:1995;860.
145. Stampfer M., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. New. Eng. J. Med. 328:1993;1444.
146. Rimm E.B., Stampler M.J., Ascherio A., Giovannuci E., Willett G.A., Colditz W.C. Vitamin E consumption and the risk of coronary heart disease in men. New. Eng. J. Med. 328:1993;1450.
147. Walldius G., Erikson U., Olsson A.G. et al. The effect of probucol on femoral atherosclerosis: the probucol quantitative regression Swedish trial (PQRST). Am. J. Cardiol. 74:1994;875.
148. The Effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. New. Eng. J. Med. 330:1994;1029.
149. Hennekens C.H., Buring J.E., Manson J.E. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. New. Eng. J. Med. 334:1996;1145.
150. Devaraj S., Adams-Huet B., Fuller C.J., Jialal I. Dose-response comparison of RRR-α-tocopherol and all-racemic α-tocopherol on LDL oxidation. Arterioscler. Thromb. Vasc. Biol. 17:1997;2273.
151. Tardif J.C., Cote B., Lesperance J. et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. New. Eng. J. Med. 337:1997;365.
152. O'Keefe J.H. Jr, Stone G.W., McCallister B.D. Jr et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 77:1996;649.
153. Schneider J.E., Berk B.C., Gravanis M.B. et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation. 88:1993;628.
154. Levine G.N., Frei B., Koulouris S.N., Gerhard M.D., Keaney J.F. Jr, Vita J.A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107.
155. Hornig B., Arakawa N., Kohler C., Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 97:1998;363.
156. Suzuki H., Kurihara Y., Takeya M. et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:1997;6622.
157. Davies M.J. The composition of coronary artery plaques. New. Eng. J. Med. 336:1997;1312.
158. Freedman J.E., Farhat J.H., Loscalzo J., Keaney J.F. Jr Tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation. 94:1996;2434.